Stock Events

Stock Events

Search...

Oxurion NV

€0.33

44

+€0+0% Today

Statistics

Day High

0.33

Day Low

0.33

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

-

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

30SepExpected

Q1 2024

Next

999

333

-333

-999

Expected EPS

N/A

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TG40.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals competes in the ophthalmology space, particularly in treatments for eye diseases, similar to Oxurion's focus on diabetic eye disease treatments.

Novartis offers a range of treatments for eye conditions, including macular degeneration and diabetic retinopathy, directly competing with Oxurion's product offerings.

Roche, through its Genentech division, develops therapies for ophthalmic diseases, competing in the same market as Oxurion, especially in the area of diabetic eye disease.

Bausch Health Companies

Bausch Health Companies, through its Bausch + Lomb segment, provides products for eye health, including treatments for retinal diseases, making it a competitor.

AbbVie, having acquired Allergan, competes in the eye care market, particularly in treatments for retinal diseases, similar to Oxurion's focus.

Biogen has ventured into ophthalmology, including treatments for retinal diseases, positioning it as a competitor in the eye disease treatment market.

The Nightview Fund NITE

Nightstar Therapeutics, acquired by Biogen, focuses on gene therapies for inherited retinal disorders, competing in the advanced treatment segment of the market.

Adverum Biotechnologies

Adverum Biotechnologies develops gene therapy products for eye diseases, including diabetic macular edema, making it a direct competitor in innovative treatments.

About

Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Show more...

CEO

Mr. Pascal Ghoson

Employees

20

Country

BE

ISIN

BE0974487192

WKN

000A40H8H

Listings